Patterns and outcomes of chemotherapy for elderly patients with stage II ovarian cancer: A population-based study

Gynecologic Oncology

Volumn 92, Issue 1, 2004, Pages 293-299

  Hershman, Dawn ^a,d   Fleischauer, Aaron T ^b   Jacobson, Judith S ^b   Grann, Victor R ^a,b   Sundararajan, Vijaya ^c   Neugut, Alfred I ^a,b  

^a College of Physicians and Surgeons ^*  (United States)

^b Columbia University ^*  (United States)

^c MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Adjuvant chemotherapy; Ovarian cancer; SEER Medicare database

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; PLATINUM DERIVATIVE;

AGED; ANALYTIC METHOD; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; EPIDEMIOLOGICAL DATA; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; OUTCOMES RESEARCH; OVARY CANCER; OVARY TUMOR; POPULATION RESEARCH; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SAMPLE; SENESCENCE; STATISTICAL MODEL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; UNITED STATES;

EID: 0742289978     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.10.006     Document Type: Article

References (34)

1. Greenlee R.T.et al. Cancer statistics, 2001. CA Cancer J. Clin. 51(1):2001;15-36.
2. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 80(7):1997;1273-1283.
3. Parker S.L.et al. Cancer statistics, 1997. CA Cancer J. Clin. 47(1):1997;5-27.
4. Ozols R.F. Outcome issues in ovarian cancer. Oncology (Huntingt). 9(Suppl. 11):1995;135-139.
5. Young R.C.et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N. Engl. J. Med. 322(15):1990;1021-1027.
6. Gibbs D.D., Gore M.E. Pursuit of optimum outcomes in ovarian cancer: methodological approaches to therapy. Drugs. 61(8):2001;1103-1120.
7. Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer. 71(Suppl. 2):1993;517-523.
8. Omura G.A.et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J. Clin. Oncol. 9(7):1991;1138-1150.
9. NIH Consensus Conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA. 273(6):1995;491-497.
10. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group. BMJ. 303(6807):1991;884-893.
11. Hannigan E.V.et al. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. Oncology. 50(Suppl. 2):1993;2-9.
12. McGuire W.P.et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334(1):1996;1-6.
13. McGuire W.P. Primary therapy of epithelial ovarian cancer. Am. Soc. Clin. Oncol. Educ. Sess. 37:2001;477-480.
14. Young R.C., Pecorelli S. Management of early ovarian cancer. Semin. Oncol. 25(3):1998;335-339.
15. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. Lancet. 352(9140):1998;1571-1576.
16. Young R., Brady M.F., Nieberg R.M.et al. Randomized clinical trial of adjuvant treatment of women with early (FIGO I-IIA high risk) ovarian cancer. Proc. Am. Soc. Clin. Oncol. 1999.
17. Bolis G.et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann. Oncol. 6(9):1995;887-893.
18. Trope C.et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann. Oncol. 11(3):2000;281-288.
19. Colombo N.et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J. Natl. Cancer Inst. 95(2):2003;125-132.
20. Trimbos J.B.et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J. Natl. Cancer Inst. 95(2):2003;113-125.
21. Trimbos J.B.et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J. Natl. Cancer Inst. 95(2):2003;105-112.
22. Potosky A.L.et al. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med. Care. 31(8):1993;732-748.
23. Cloven N.G.et al. Management of ovarian cancer in patients older than 80 years of age. Gynecol. Oncol. 73(1):1999;137-139.
24. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 45(6):1992;613-619.
25. Charlson M.E.et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40(5):1987;373-383.
26. Warren J.L.et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med. Care. 40(Suppl. 8):2002;IV-55-IV-61.
27. Gershenson D. Advances in the management of early-stage epithelial ovarian cancer. Am. Soc. of Clin. Oncol. 2001.
28. Sundararajan V.et al. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J. Clin. Oncol. 20(1):2002;173-178.
29. Vergot I.B., Trimbos B.G.M.P.et al. Results of a randomized trial in 923 patients with high-risk early ovarian cancer, comparing adjuvant chemotherapy with no further treatment following surgery. Proc. Am. Soc. of Clin. Oncol. 2001;. San Fancisco.
30. McGuire W.P.H.W., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Davidson M. Taxol and cisplatin (TP) improves outcome in advanced ovarian cancer (AOC) as compared to cytoxan and cisplatin (CP). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1993.
31. Antman K.et al. Selection bias in clinical trials. J. Clin. Oncol. 3(8):1985;1142-1147.
32. McGowan L.et al. Misstaging of ovarian cancer. Obstet. Gynecol. 65(4):1985;568-572.
33. Young R.C.et al. Staging laparotomy in early ovarian cancer. JAMA. 250(22):1983;3072-3076.
34. Le T.et al. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol. Oncol. 85(2):2002;351-355.